RT Journal Article
SR Electronic
T1 A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.07.08.193045
DO 10.1101/2020.07.08.193045
A1 Lorena Sanchez Felipe
A1 Thomas Vercruysse
A1 Sapna Sharma
A1 Ji Ma
A1 Viktor Lemmens
A1 Dominique van Looveren
A1 Mahadesh Prasad Arkalagud Javarappa
A1 Robbert Boudewijns
A1 Bert Malengier-Devlies
A1 Suzanne F. Kaptein
A1 Laurens Liesenborghs
A1 Carolien De Keyzer
A1 Lindsey Bervoets
A1 Madina Rasulova
A1 Laura Seldeslachts
A1 Sander Jansen
A1 Michael Bright Yakass
A1 Osbourne Quaye
A1 Li-Hsin Li
A1 Xin Zhang
A1 Sebastiaan ter Horst
A1 Niraj Mishra
A1 Lotte Coelmont
A1 Christopher Cawthorne
A1 Koen Van Laere
A1 Ghislain Opdenakker
A1 Greetje Van de Velde
A1 Birgit Weynand
A1 Dirk E. Teuwen
A1 Patrick Matthys
A1 Johan Neyts
A1 Hendrik Jan Thibaut
A1 Kai Dallmeier
YR 2020
UL http://biorxiv.org/content/early/2020/07/09/2020.07.08.193045.abstract
AB The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.Competing Interest StatementThe authors have declared no competing interest.